1. Home
  2. CDNA vs ARQT Comparison

CDNA vs ARQT Comparison

Compare CDNA & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$18.09

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$22.74

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDNA
ARQT
Founded
1998
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
3.3B
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
CDNA
ARQT
Price
$18.09
$22.74
Analyst Decision
Buy
Strong Buy
Analyst Count
7
6
Target Price
$27.33
$34.00
AVG Volume (30 Days)
541.6K
1.2M
Earning Date
04-29-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
88.79
EPS
N/A
N/A
Revenue
$48,324,000.00
$376,072,000.00
Revenue This Year
$16.01
$34.46
Revenue Next Year
$11.31
$29.77
P/E Ratio
N/A
N/A
Revenue Growth
18.93
91.34
52 Week Low
$10.96
$11.86
52 Week High
$21.49
$31.77

Technical Indicators

Market Signals
Indicator
CDNA
ARQT
Relative Strength Index (RSI) 49.67 40.88
Support Level $16.62 $22.56
Resistance Level $20.94 $27.26
Average True Range (ATR) 0.69 0.87
MACD 0.11 -0.06
Stochastic Oscillator 67.16 30.49

Price Performance

Historical Comparison
CDNA
ARQT

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Share on Social Networks: